Adult-onset Still's disease (AOSD) is an uncommon inflammatory condition characterised by high fever, leukocytosis with neutrophilia, arthralgia and skin rash. Diagnosis is often clinical, and it is always necessary to exclude common disease mimics such as infections, malignancies and other rheumatic diseases. Ferritin and glycosylated ferritin are useful adjuncts to aid in the diagnosis of AOSD. Important complications to consider include fulminant hepatitis, disseminated intravascular coagulopathy and hemophagocytic syndrome. Mainstay treatment of AOSD is often with glucocorticoids. Other agents that can also be used include methotrexate, and biologic therapy, such as tumor necrosis factor-α (TNF-α) blockers and interleukin-1 (IL-1) inhibitors. A retrospective review of patients diagnosed with AOSD admitted to Singapore General Hospital (SGH) was performed, and their disease characteristics and laboratory findings were compared with that of previous published cohorts.
INtRODUctION
AOSD is a rare systemic inflammatory disorder that is characterised by high-spiking fevers with an evanescent, non-pruritic, macular and salmon-coloured rash appearing on the trunk and extremities, arthritis, and multi-organ involvement. Still's disease was first described by an English physician, Sir George Frederic Still, who published in 1897 his monograph, On a Form of Chronic Joint Disease in Children, describing 22 children with signs and symptoms of the disease entity currently known as systemic onset juvenile idiopathic arthritis 1 . In 1971, Eric Bywaters described 14 adults with similar presentation with systemic onset juvenile idiopathic arthritis 2 .
EPIDEMIOLOGY AOSD has a prevalence estimated at less than one case per 100,000 people 3 . By definition, AOSD affects patients older than 16 years old. Age of presentation is often between 16 to 35 years of age 2 , but elderly onset AOSD has also been described 4 . Females appear to be more frequently affected than males 2 .
Thus far, no familial trend has been reported, but studies have described an association of AOSD with HLA alleles, namely HLA-DR4, B17, B18, B35, DR2, DR5 and DQ1 5 . HLA-DRB1*04 may be protective of the disease, whilst HLA-Bw35 conferred a better prognosis 6 . HLA-DRB1*14 alleles were more common in patients with the monocyclic systemic type of AOSD 7 , whilst chronic articular form of the disease was associated with HLA-DR2, DR5 and DQ1 alleles 8 .
Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 a hallmark of AOSD, and is mediated by TNF-α, IL-1, interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-18 . Over the past decade, the potential role of T-helper (Th) cells in the pathogenesis of AOSD has been emerging. Chen et al found higher interferon-γ (IFNγ)-producing Th cells and higher Th1/Th2 ratios in the peripheral blood of AOSD patients compared with healthy controls, and these correlated with the clinical activity score and serum IL-18 levels in patients with AOSD 10 . Increased ratio of Th1/Th2 cytokine transcripts were also seen in the biopsy specimens of evanescent rash and synovitis from patients with AOSD. With treatment, clinical remission was associated with a marked decrease in the proportion of Th1 cells.
Th17 cells have also recently been implicated in the pathogenesis of AOSD. The frequencies of circulating Th17 cells positively correlated with the activity score, serum ferritin levels and serum levels of IL-1b, IL-6, IL-17, IL-18, IL-21 and IL-23 in AOSD patients 11 . Frequencies of circulating Th17 cells decreased after effective therapy. Another potential source of IL-17 production is from Tγ/δ cells, and increased levels of T-cell receptor γδ-positive (TCRγδ+) T-cells have previously been associated with active disease and raised inflammatory markers 12 .
CD4+CD25 (high) regulatory T (Treg) cells are also involved in the pathogenesis of AOSD. Treg cells have been found to be low in AOSD patients as compared to healthy controls, and inversely associated with disease activity 13 . Higher levels of CD4+CD25 (high) Treg cell activity have also been associated with a monocyclic pattern of disease.
Many cytokines have been implicated in the pathogenesis of AOSD, including TNF-α 14 , IL-1β 15 , soluble IL-2 receptor (sIL-2R) 16 , IL-6 16 , IL-8 16 , IL-17 17 and IL-18 18 . Of interest is that local expression of IL-18 by CD68+ liver macrophages is markedly increased in the liver parenchyma of AOSD patients with active hepatitis 19 . IL-18 levels were also significantly higher in those with active disease and correlated with serum ferritin levels and neutrophil counts. Interestingly, gene -607 (C/A) IL-18 promoter polymorphisms present in Chinese patients are associated with lower IL-18 levels 20 . This could possibly account for the much lower incidence of transaminitis observed in our patient cohort. However, measurements of cytokines are not useful when trying to differentiate between bacterial sepsis and active AOSD in the clinical setting. Serum cytokine levels of IL-1ß, IL-6, IL-8, IL-10, IL-12, IL-18, IFN-γ, TNF-α, and calprotectin are elevated both in patients with acute AOSD and sepsis 21 .
Potentially useful markers of disease activity and severity include CD64 22 , calprotectin 23 , macrophage inhibitory factor 24 , intercellular adhesion molecule-1 25 and macrophage-colony stimulating factor 26 .
cLINIcAL MANIFEStAtIONS
The common manifestations of AOSD are fever, arthralgia, rash and sore throat. Fever is often cyclical, with temperature spikes of >39 0 C, frequently in the evening, associated with chills and rigours. Fever is associated with joint pain and rashes. Joint pain is maximal during fever spikes, migratory at onset before becoming constant later. Inflammatory arthritis can be symmetrical or asymmetrical, and any joint can be involved. Chronic arthritis may evolve into a more erosive form and bilateral ankylosing carpal arthritis is a classic feature. The typical rash of AOSD is that of small, discrete, non-pruritic, salmon-pink maculopapules, which is transient and often coincides with the fever spikes. It can occur on the proximal limbs or trunk, and rarely involves the face, palms or soles of the feet. The rashes are non-scarring 9 , and can exhibit the Koebner phenomenon 27 . Rashes that appear purpuric should be further investigated to exclude disseminated intravascular coagulation (DIC) and hemophagocytic syndrome. Sore throat affects between 70% to 90% of the patients 5, 28, 29 , and is due to a non-suppurative pharyngitis 2 .
Over a span of eight years, 17 patients have been diagnosed by rheumatologists to have AOSD in SGH, with a median age at presentation of 45 years (range 16-68 years). The median duration of symptoms from onset to diagnosis was two months (range 10 days-60 months). Females made up 70.6% of our patients; 82.4% of our patients were Chinese, with two others being a Filipino and a Bangladeshi, respectively. 15 (84%) patients fulfilled the Yamaguchi criteria 30 . A retrospective review of our patients showed the following common presenting symptoms: fever (100%), typical rash (94%), inflammatory arthritis (77%) and constitutional symptoms (53%), comparable to other series (Table 1) 31 and our patient series. Also, none of our patients had pleuritis or pericarditis, even though this occurred in 19% of patients in the cohort by Mok et al 31 . In our patients, wrist (53%), knee (53%) and ankle (29%) joints were most commonly affected, and this was similar to patients described by Riera et al 29 . In contrast, fewer of our patients had metacarpophalangeal joint involvement (11.8%) and none had hip joint or distal interphalangeal joint involvement (Table 2) .
INVEStIGAtIONS
The majority of our patients had an erythrocyte sedimentation rate (ESR) of >40mm/hour (100%), negative antinuclear antibody (ANA) (94%) and white blood cell count >10,000/mm 3 (82%), which is comparable to other series (Table 3 ). Of note was the much lower incidence of transaminitis (6%), hyperferritinaemia (41%) and negative rheumatoid factor (65%) ( Table 3 ). Hyperferritinaemia has been previously described in cases of AOSD 32 , and it is an indicator of disease activity due to macrophage activation 33 . However, ferritin has poor predictive value when used to diagnose AOSD without appropriate clinical features, regardless of the threshold used 34 . Hyperferritinaemia is also noted to be raised in other diseases, such as liver diseases (especially haemochromatosis and Gaucher's disease), kidney diseases, cancers, and various infections, notably acquired immune deficiency syndrome 35 
NAtURAL HIStORY OF AOSD
The natural history of AOSD has been described commonly in three patterns 42 . The monocyclic pattern is usually associated with a single flare of the disease with complete remission within two to four weeks, and represents 19% to 44% of cases. The polycyclic pattern is seen in 10% to 41% of cases and is characterised by recurrent systemic or articular flares of the disease separated by periods of clinical remission lasting from two weeks to two years. The chronic articular form is seen in 35% to 67% of cases, and one-third of the patients can develop erosive arthritis.
cOMPLIcAtIONS OF AOSD
Important complications that can result from AOSD include liver failure secondary to fulminant hepatitis, DIC, and hemophagocytic syndrome. Fulminant hepatitis requiring molecular absorbent recirculating system (MARS) therapy and liver transplantation is rare and has been described in four patients to date 43 . The onset of fulminant hepatitis could occur either concomitantly at initial diagnosis or as late as three years after the initial diagnosis. All the cases were noted to have hepatic involvement at the time of AOSD diagnosis, and all had massive necrosis on liver histology. Hepatic encephalopathy complicating acute liver failure is secondary to accumulation of toxins such as bilirubin, bile acids, tryptophan, aromatic amino acids and ammonia in the blood. This is due to the inability of hepatocytes to clear these molecules from the circulation. MARS is an extracorporeal liver assistance device that utilises an albumin dialysate for the removal of albumin-bound toxins, and could benefit patients in the interim whilst waiting for an organ to be available for liver transplant.
DIC is another important complication to look out for. This would normally manifest as bleeding of the gums, mouth, nose, and venipuncture sites. Haemorrhagic strokes, haemothorax, intra-and extra-peritoneal bleeding can result in mortality if not treated early. Features of DIC include prolongation of the prothrombin and activated thromboplastin time, thrombocytopaenia, low levels of fibrinogen, and increased fibrin degradation products. Treatment of DIC should primarily be focused on addressing the underlying disorder. Platelet and factor replacement should not be to simply correct laboratory abnormalities, but to address bleeding concerns and minimise bleeding during procedures.
Hemophagocytic syndrome is a rare but lifethreatening complication of AOSD. Prevalence of hemophagocytic syndrome in AOSD has been reported as 12% 44 . It is also known as "hemophagocytic lymphohistiocytosis" or "macrophage activation syndrome". Hemophagocytic syndrome is a clinicopathological syndrome characterised by hyperpyrexia, hepatosplenomegaly, transaminitis and elevated serum ferritin levels, all of which are also features of AOSD. Distinguishing features include that of decreased ESR and cytopenias, as compared to a raised ESR and leukocytosis which is usually present in AOSD flares. Neuropsychiatric manifestations are also more common in hemophagocytic syndrome compared to AOSD, and include coma, seizures, meningism, mood disorders, delirium, psychosis and cognitive dysfunction. Histology is of utmost importance to look for the presence of hemophagocytes in the bone marrow trephine, as well as hemophagocytes in organs involved, such as the liver, spleen and lymph nodes. However, it is important to note that absence of hemophagocytes can occur in up to 20% of initial bone marrow specimens 45 .
The diagnostic criteria for hemophagocytic syndrome by Henter et al in 2007 requires the presence of five of more of the following criteria: fever (>38.5 0 C for at least seven days), splenomegaly, cytopenias affecting ≥2 of 3 cell lineages (haemoglobin <90g/L, platelets <100x10 9 /L, neutrophils <1x10 9 /L), hypertriglyceridemia (fasting triglycerides ≥3mmol/L) or hypofibrinogenemia Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 (≤1.5g/L), hemophagocytosis in bone marrow or spleen or lymph nodes, no evidence of malignancy, low or absent natural killer (NK) cell activity, ferritin ≥500μg/L or soluble CD25 ≥2400U/ml 46 . However, these criteria are not always fulfilled in patients with rheumatic diseases.
Hemophagocytic syndrome is a result of increased proliferation and activation of benign macrophages, leading to a continuous immune activation and cytokine storm, with hemophagocytosis occurring throughout the reticuloendothelial system due to increased IL-18 levels. Treatment of hemophagocytic syndrome consists of managing the underlying autoimmune disease. Traditionally, treatment regimens required parenteral administration of high doses of corticosteroids. However, this still resulted in significant mortality 48 , and was usually only effective in about half of the patients 49 . Ciclosporin A (CsA) has been shown to be effective in treating hemophagocytic syndrome in children 50 , and this has been successfully extended to the treatment of hemophagocytosis in AOSD 51 . Trough levels of CsA were maintained at around 250ng/ml, and six cycles of plasmapharesis were performed. It has been shown that CsA suppresses T-cell and macrophage activation, leading to failure of transcription of genes that encode for cytokines, possibly explaining its effectiveness in the treatment of hemophagocytic syndrome in AOSD. Similar efficacy of CsA was also echoed by Fukaya et al, and it was further noted that tacrolimus may be considered when CsA is ineffective 49 . Other agents which have been used to varying degrees of efficacy include TNF-α blockers such as etanercept, IL-1 inhibitors such as anakinra, and rituximab 49 . Poor prognostic factors for autoimmune-related hemophagocytic syndrome included the absence of lymphadenopathy, thrombocytopenia of <50x10 9 /L, infections and corticosteroid therapy at the time of diagnosis of hemophagocytic syndrome 49 .
tREAtMENt OF AOSD
Treatment of AOSD is based largely on observational studies and retrospective analysis due to its rarity. Unlike systemic onset juvenile idiopathic arthritis, non-steroidal anti-inflammatory drugs are only effective in 20% of patients, the most effective being indomethacin 5 . Corticosteroids are usually required to induce remission, however, this is only effective in up to 80% of cases and tapering of steroids can lead to relapse of disease 9 . Hence, a variety of disease modifying antirheumatic drugs (DMARDs) have been used as steroid sparing agents, including azathioprine, hydroxychloroquine, leflunomide, mycophenolate mofetil, cyclosporine A, intravenous immunoglobulins and most commonly, methotrexate 9, [52] [53] [54] . In a multicentre study conducted in France, 13 of 64 AOSD patients received methotrexate as a DMARD, and 85% were subsequently able to taper their steroid dose 55 . The authors then analysed the efficacy of methotrexate as a second-line drug in 26 patients, and found that the majority demonstrated a clinical response, whilst about one-third of the patients achieving complete remission. Similar efficacy of methotrexate in AOSD was also seen by Fujii et al 56 . Remission was achieved in 8 of 13 (62%) patients, with five of eight (63%) patients able to stop corticosteroids completely. The inhibitory effects of methotrexate on IL-1 production and activity could account for its efficacy in AOSD, as IL-1 triggered events in the inflammatory cascade play a key role in AOSD.
Sulfasalazine is not recommended in AOSD as it may have more side-effects compared to other DMARDs 57 . A review of 10 patients given sulfasalazine for treatment of arthritis in AOSD showed that 60% of patients developed sideeffects ranging from abdominal pain, nausea, vomiting, urticaria and facial flushing to hypotension, hepatitis and myelosuppression 57 . Development of hemophagocytic syndrome after initiation of sulfasalazine has also been described in case reports, possibly due to the reactivation of the Epstein-Barr virus 58, 59 .
Biologics such as TNF-α blockers (e.g. Adalimumab 60 , infliximab and etanercept 61 ), IL-1 inhibitors (e.g. anakinra 62 , rilonacept 63 and cankinumab 64 ), IL-6 inhibitors (e.g. tocilizumab 65 ) and T-cell costimulation blockade (e.g. abatacept 66 ) have shown good efficacy in AOSD patients refractory to conventional DMARD therapy.
In conclusion, AOSD has protean manifestations and can be associated with life-threatening complications, such as hemophagocytic syndrome and liver failure. AOSD remains a clinical diagnosis, with early diagnosis being a challenge, as infections and malignancies can present in a similar manner.
